MAZE — Maze Therapeutics, Inc.

Is MAZE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Maze Therapeutics, Inc. (MAZE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $29.13. The rating moved from Oversold to Overbought on August 18, 2026.

See all overbought Healthcare stocks →

AI analysis

Maze Therapeutics, Inc. is positioned as an early-stage biotech where valuation is highly dependent on clinical progress, capital markets access, and potential partnerships. Current market tone is mildly supportive for biologics and growth-oriented names, which could provide short-term upside, but public data gaps on filings and financials raise uncertainty about cash runway and near-term dilution risk. Key catalysts that would materially change the outlook include positive clinical readouts, strategic collaborations, or clearer financing plans. Offsetting upsides are the competitive landscape, payer/reimbursement pressures, regulatory timelines, and the typical binary outcomes of clinical development. Near-term price action will likely track sector flows and any news about clinical milestones or financing events.

Key factors

  • Sector tailwinds for biologics and CRO/CDMO services could indirectly benefit Maze via greater investor interest in biologics-focused names and potential partnerships or outsourcing demand.
  • Clinical-stage biotech profile: upside tied to clinical data readouts or partnership/licensing events that could materially re-rate the equity.
  • Limited public disclosure in the provided dataset (no recent EDGAR comparison), creating uncertainty around cash runway, revenue, and near-term milestones.
  • Macro and market tone is mildly risk-on due to tech earnings and rate stability expectations, which can support small-cap biotech rallies in the near term.
  • Payer and reimbursement environment is evolving (insurer focus on analytics and margin defense), which could complicate future commercialization and pricing dynamics for therapeutics.

Risks

  • Clinical trial failure or negative clinical data that would materially reduce the company's valuation.
  • Need for near-term financing leading to dilution if cash runway is insufficient; lack of EDGAR details increases uncertainty on timing and size.
  • Regulatory setbacks or delays in approvals that push out commercialization timelines.
  • Competitive risk from larger pharma/biotech incumbents or other genetic/biologics developers targeting similar indications.
  • Reimbursement and payer pressure (MA plan pruning, analytics-driven coverage decisions) that could limit market access or pricing power.
  • Low liquidity and elevated share-price volatility common to small-cap clinical biotechs.
  • Macro/market shocks (inflation surprises, geopolitical events) that reverse current risk-on sentiment and compress biotech multiples.

See today's live rating, score and targets

Members see the live hourly rating for MAZE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.